Holen Sie sich die Stockscreener-App
17.83
0.89%
-0.16
Handel nachbörslich:
17.85
0.02
+0.11%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
UnitedHealthcare limits coverage for Myriad's GeneSight test - Investing.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out - AccessWire
Myriad Genetics (NASDAQ:MYGN) Shares Down 4.6%Here's Why - MarketBeat
Myriad Genetics Inc (MYGN) Trading Down 3.81% on Nov 4 - GuruFocus.com
Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight - MarketWatch
UnitedHealthcare limits coverage for Myriad's GeneSight test By Investing.com - Investing.com UK
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing - GlobeNewswire
Trading (MYGN) With Integrated Risk Controls - Stock Traders Daily
Myriad weakness due to UnitedHealth coverage update, says Stephens - Yahoo Finance
Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge - Simply Wall St
Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment? - Simply Wall St
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Myriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes - MarketWatch
Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage - Seeking Alpha
Myriad Genetics (NASDAQ:MYGN) Shares Gap DownWhat's Next? - MarketBeat
Myriad Genetics (MYGN) to Release Quarterly Earnings on Thursday - MarketBeat
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024 - GlobeNewswire
Assenagon Asset Management S.A. Reduces Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Myriad Genetics 2008A Retrospective - RTTNews
Myriad Genetics Q4 Profit Declines, Yet Tops EstimateUpdate - RTTNews
Myriad Genetics Swings to Q3 Profit - RTTNews
Myriad Genetics Q1 Profit More Than Doubles, Yet Misses Estimate - RTTNews
Making Peace With Rivals For A Slice Of BRCA... - RTTNews
Relationship Tests Market Size 2024: Industry Overview, - openPR
What We Don’t Know Can Hurt: New Survey Reveals Knowledge Gaps About Breast Density and Cancer Risk - North American Precis Syndicate, Inc.
(MYGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Myriad: Q2 Earnings Snapshot - Barchart
Myriad Genetics Shares Fall Despite Partnership With jscreen - Yahoo Finance
OmniStar Financial Group Inc. Makes New $863,000 Investment in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Direct-To-Consumer Genetic Testing Market to Grow by USD 1.22 Billion from 2024-2028, Driven by Early Disease Diagnosis and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Myriad Genetics partners with jscreen for genetic testing By Investing.com - Investing.com Australia
Myriad Genetics partners with jscreen for genetic testing - Investing.com
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access - GlobeNewswire
21,968 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Purchased by Sanctuary Advisors LLC - MarketBeat
Myriad's MyRisk test integrated into Flatiron's OncoEMR - Investing.com
Myriad's MyRisk test integrated into Flatiron's OncoEMR By Investing.com - Investing.com Canada
Myriad Genetics and Flatiron Health Partner to Make Genetic - GlobeNewswire
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration - StockTitan
Cancer Genomic Testing Market – 37% of Growth to Originate from APAC -Myriad Genetics, Centogene AG, Color Genomics, Que – IndiaPolitics.com - IndiaPolitics.com
Scotiabank reiterates positive outlook on Myriad Genetics shares By Investing.com - Investing.com UK
SG Americas Securities LLC Takes $649,000 Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Global Consumer Genomics Market Huge Growth in Future Scope - openPR
Myriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past week - Yahoo Finance
Brokers Offer Predictions for Myriad Genetics, Inc.'s Q1 2025 Earnings (NASDAQ:MYGN) - MarketBeat
Learn to Evaluate (MYGN) using the Charts - Stock Traders Daily
Myriad Genetics, Inc. (NASDAQ:MYGN) CEO Sells 15,000 Shares - MarketBeat
Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN) - GuruFocus.com
Myriad Genetics CEO Paul J. Diaz sells $343,950 in stock By Investing.com - Investing.com South Africa
Myriad Genetics CEO Paul J. Diaz sells $343,950 in stock - Investing.com
Insiders At Myriad Genetics Sold US$6.5m In Stock, Alluding To Potential Weakness - Simply Wall St
Pharmacogenomics Industry Report 2024: Analysis by Technology, Application, End-user, Region, and Company with Growth Forecasts to 2032 - GlobeNewswire Inc.
Stephens increases Myriad Genetics stock target on growth outlook By Investing.com - Investing.com Canada
Breast Cancer Liquid Biopsy Market is expected to Double Its Size - openPR
MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests - Yahoo Finance
Leerink maintains Outperform rating on Myriad Genetics stock with updated revenue estimates - Investing.com Canada
JPMorgan attends Myriad Genetics investor day, holds stock rating at Underweight By Investing.com - Investing.com Canada
Myriad Genetics (NASDAQ:MYGN) Shares Gap UpStill a Buy? - MarketBeat
Myriad Genetics advances breast cancer MRD testing research By Investing.com - Investing.com Australia
0.73%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):